CCNF and lung adenocarcinoma: Moreover, for disease-specific survival (DSS), high CCNF expression significantly contributed to poorer clinical outcomes in KIRC, LIHC, KIRP, LGG, ACC, lung adenocarcinoma (LUAD), MESO, and SKCM (Figure S3).